Planned sale of 8,020 HCA (HCA) shares under Rule 144
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
A shareholder of HCA Healthcare, Inc. filed a Rule 144 notice to sell 8,020 shares of common stock, with an aggregate market value of 4,126,949.9. The planned sale is through Merrill Lynch on the NYSE, with an approximate sale date of 02/11/2026.
The shares to be sold were acquired via vesting of stock awards from HCA Healthcare, Inc. on 02/17/2023 (5,159 shares), 02/16/2024 (1,680 shares), and 02/13/2025 (1,181 shares), each described as a compensatory payment. The notice also states that the seller represents they do not know any undisclosed material adverse information about HCA’s operations.
Positive
- None.
Negative
- None.
FAQ
What does the Form 144 filing for HCA indicate?
The Form 144 indicates a shareholder plans to sell 8,020 HCA Healthcare common shares under Rule 144. The planned transaction has an aggregate market value of 4,126,949.9 and is scheduled for execution on or around 02/11/2026 through Merrill Lynch on the NYSE.
What representation does the seller make in the HCA Form 144?
The seller represents that they do not know any material adverse information about HCA Healthcare’s current or prospective operations that has not been publicly disclosed. This representation is explicitly stated as part of signing the notice required for the planned Rule 144 sale.
Does the HCA Form 144 mention Rule 10b5-1 trading plans?
Yes. The notice explains that if the person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1, by signing they make the same representation as of the plan’s adoption or instruction date, regarding undisclosed material adverse information.